Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors
Shots: The first patient has been dosed in a P-I CIBI323A101 study evaluating IBI323 (anti-LAG-3/PD-L1 bispecific Ab) in patients with advanced solid tumors. The trial is being conducted in China The purpose of the P-I dose-escalation and expansion study is to evaluate the safety, tolerability, optimal dosage, and preliminary efficacy of IBI323 in patients with […]